Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

Lorusso, Domenica; Naldini, Angelica; Testa, Antonia Carla; D’Agostino, Giuseppe; Scambia, Giovanni

doi:10.1159/000081324

Cited by 34 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16][17][19][20][21][22][23][24][25][26] PLD required fewer dose modifications compared with topotecan and gemcitabine. The superiority of PLD in terms of QOL has been shown.…”

Section: Safetymentioning

confidence: 99%

Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens

Sugiyama

Kumagai

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Pegylated liposomal doxorubicin (PLD) is doxorubicin HCl encapsulated in long-circulating STEALTH® liposomes (Doxil ® ). PLD achieves good response rates and many patients maintain long-lasting stable disease (SD), which is one of the advantages. In addition, the clinical benefit is high in platinum-resistant disease, and PLD is thus considered to be the first option. PLD is associated with a number of adverse events, but these events are mild to moderate. PLD is safer for heavily pretreated patients than topotecan and gemcitabine due to mild bone-marrow toxicity, but that nonhematotoxity, such as PPE, stomatitis, mucositis, and other cutaneous reactions were the most common side effects attributable to PLD. Based on a review of previous studies, there are no differences in efficacy between 50 and 40 mg/m 2 of PLD, therefore, a dose of 40 mg/m 2 is preferable in patients with platinum-resistant disease to reduce adverse events. The 1-hour infusion schedule every 4 weeks makes PLD easy to administer. A rational approach to combine PLD with other drugs should take the slow accumulation and delayed peak of PLD in tumors into consideration. When combined with other useful agents, the lower dose of PLD (30 to 35 mg/m 2 ) with a 3-week schedule may reduce severe PPE and stomatitis with negligible effects on the level of DI and the therapeutic efficacy.

show abstract

“…[14][15][16][17][19][20][21][22][23][24][25][26] PLD required fewer dose modifications compared with topotecan and gemcitabine. The superiority of PLD in terms of QOL has been shown.…”

Section: Safetymentioning

confidence: 99%

Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens

Sugiyama

Kumagai

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

show abstract

“…A summary of phase II studies using PLD as a single agent or in combination regimens in ovarian cancer is presented in Table 1 [26–35]. …”

Section: Pegylated Liposomal Doxorubicin: Activity In Ovarian Cancermentioning

confidence: 99%

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Pisano¹,

Cecere²,

Napoli³

et al. 2013

Journal of Drug Delivery

View full text Add to dashboard Cite

Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation. Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. In 1999 it was first approved for platinum-refractory ovarian cancer and then received full approval for platinum-sensitive recurrent disease in 2005. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Recent interest in PLD/carboplatin combination therapy has been the object of phase III trials in platinum-sensitive and chemonaïve ovarian cancer patients reporting response rates, progressive-free survival, and overall survival similar to other platinum-based combinations, but with a more favorable toxicity profile and convenient dosing schedule. This paper summarizes data clarifying the role of pegylated liposomal doxorubicin (PLD) in ovarian cancer, as well as researches focusing on adding novel targeted drugs to this cytotoxic agent.

show abstract

“…In clinical practice, oncologists were surprised by the high incidence of HFS (Table 16.2). Reducing PLD dose intensity is a standard approach used to reduce the risk of or to ameliorate HFS and has been used in patients with several tumor types including breast cancer and ovarian cancer [20,[32][33][34][35][36]. Collectively studies demonstrate that PLD administered at a dose intensity of 10 mg/m 2 /week, regardless of the dosing interval, is well tolerated and effective (Table 16.2) At this dose intensity most HFS is mild to moderate and potentially disabling HFS does not occur.…”

Section: Nail Changesmentioning

confidence: 99%

Topoisomerase‐Interacting Agents

Skácel

Moos

Dummer

2013

Dermatologic Principles and Practice in Oncology

View full text Add to dashboard Cite

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

Cited by 34 publications

References 33 publications

Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens

Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Topoisomerase‐Interacting Agents

Contact Info

Product

Resources

About